Discover how the HEK293-derived Pro10™ cell line accelerates AAV vector production. This whitepaper explores a scalable, animal component-free platform that reduces process development time and costs, meeting growing clinical and commercial demands for gene therapies.
Viralgen, founded in 2017 as a subsidiary of AskBio within the Bayer AG group, is a premier CDMO specializing in AAV-based gene therapies delivering end-to-end support from construct optimization and plasmid DNA production through large-scale clinical and commercial manufacturing. Leveraging the Aava™ manufacturing platform built upon its proprietary Pro10™ suspension cell line, Viralgen achieves industry-leading, high-yield, scalable manufacturing across all AAV serotypes, in the world’s largest AAV-dedicated facility, to help clients scale efficiently, optimize cost of goods, and mitigate risk.
Viralgen, founded in 2017 as a subsidiary of AskBio within the Bayer AG group, is a premier CDMO specializing in AAV-based gene therapies delivering end-to-end support from construct optimization and plasmid DNA production through large-scale clinical and commercial manufacturing. Leveraging the Aava™ manufacturing platform built upon its proprietary Pro10™ suspension cell line, Viralgen achieves industry-leading, high-yield, scalable manufacturing across all AAV serotypes, in the world’s largest AAV-dedicated facility, to help clients scale efficiently, optimize cost of goods, and mitigate risk.